Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from CellSource Co., Ltd. ( (JP:4880) ).
CellSource Co., Ltd. has resolved to apply to move its listing from the Tokyo Stock Exchange Prime Market to the Standard Market after weak business performance in the fiscal year ended October 31, 2025 caused it to fall below the Prime Market’s continued listing requirement of at least ¥10 billion in market capitalization of tradable shares. While acknowledging it would be difficult to meet the Prime criteria in the current environment, the company said the Standard Market, which still ensures a certain level of governance and liquidity, better matches its present business scale and market conditions, and that it already satisfies all the Standard Market listing examination criteria. The timing of approval remains undecided and the application could still be rejected if requirements are ultimately deemed unmet, but CellSource emphasized it will continue working to enhance its corporate value over the medium to long term and will disclose further developments as needed.
The most recent analyst rating on (JP:4880) stock is a Hold with a Yen455.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. is a Japan-based company focused on the industrialization of regenerative medicine-related businesses. The company is currently listed on the Tokyo Stock Exchange and targets investors interested in healthcare and biotech growth opportunities within Japan’s capital markets.
Average Trading Volume: 103,777
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.95B
See more data about 4880 stock on TipRanks’ Stock Analysis page.